Clinical Policy: Topotecan (Hycamtin)
Reference Number: CP.PHAR.64
Effective Date: 06.01.11
Last Review Date: 05.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Topotecan (Hycamtin®) is a topoisomerase inhibitor.

FDA Approved Indication(s)
Hycamtin capsules are indicated for the treatment of relapsed small cell lung cancer in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy.

Hycamtin for injection is indicated:
- As a single agent for the treatment of patients with metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy
- As a single agent for the treatment of patients with small cell lung cancer with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy
- In combination with cisplatin for the treatment of patients with Stage IV-B, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Hycamtin is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Ovarian Cancer (must meet all):
      1. Diagnosis of ovarian cancer;
      2. Request is for topotecan for injection;
      3. Prescribed by or in consultation with an oncologist;
      4. Age ≥ 18 years;
      5. Disease progression on or after initial or subsequent chemotherapy;
      6. Request meets one of the following (a or b):*
         a. Dose does not exceed 1.5 mg/m² per day for 5 consecutive days every 21 days;
         b. Requested dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
   *Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
CLINICAL POLICY
Topotecan

Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

B. Small Cell Lung Cancer (must meet all):
1. Diagnosis of small cell lung cancer;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Member has received prior chemotherapy;
5. Request meets one of the following (a or b):
   a. Dose does not exceed the following:
      i. Injection: 1.5 mg/m² per day IV for 5 consecutive days every 21 days;
      ii. Capsule: 2.3 mg/m² per day orally for 5 consecutive days every 21 days;
   b. Requested dose is supported by practice guidelines or peer-reviewed literature for
      the relevant off-label use (prescriber must submit supporting evidence).

   *Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer
(injection); Length of Benefit (capsule)

C. Cervical Cancer (must meet all):
1. Diagnosis of cervical cancer;
2. Request is for topotecan for injection;
3. Prescribed by or in consultation with an oncologist;
4. Age ≥ 18 years;
5. Request meets one of the following (a or b):
   a. Dose does not exceed 0.75 mg/m² on days 1-3 every 21 days;
   b. Requested dose is supported by practice guidelines or peer-reviewed literature for
      the relevant off-label use (prescriber must submit supporting evidence).

   *Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer

D. NCCN Recommended Uses (off-label) (must meet all):
1. Prescribed for one of the following diagnoses:
   a. Request is for topotecan for injection:
      i. Ewing sarcoma;
      ii. Osteosarcoma;
      iii. Primary CNS lymphoma;
      iv. Leptomeningeal metastases and route of administration is intrathecal;
      v. Rhabdomyosarcoma;
      vi. Endometrial carcinoma;
   b. Request is for topotecan for injection or topotecan capsules:
i. Merkel cell carcinoma and member has contraindications to checkpoint immunotherapy (e.g., avelumab, pembrolizumab, nivolumab);
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Dose is within FDA maximum limit for any FDA approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).*

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer (injection); Length of Benefit (capsule)

E. Other diagnoses/indications
Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. All Indications in Section I (must meet all):
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Hycamtin for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
   a. New dose does not exceed the following:
      i. Ovarian cancer: 1.5 mg/m²/day IV for 5 consecutive days every 21 days;
      ii. Small cell lung cancer: 1.5 mg/m²/day IV or 2.3 mg/m²/day orally for 5 consecutive days repeated every 21 days;
      iii. Cervical cancer: 0.75 mg/m² IV on days 1-3 every 21 days;
   b. Requested dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Medicaid/HIM – 12 months
Commercial – 6 months or to the member’s renewal date, whichever is longer (injection); Length of Benefit (capsule)

B. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is
III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration
NCCN: National Comprehensive Cancer Network

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings
- Contraindication(s): History of severe hypersensitivity reactions to topotecan
- Boxed warning(s): Myelosuppression

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
</table>
| Ovarian cancer        | IV infusion dosage:
1.5 mg/m² IV over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course | 4 mg/dose if IV infusion, otherwise refer to regimen |
| Small cell lung cancer| IV infusion dosage:
1.5 mg/m² IV over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course
Oral dosage: 2.3 mg/m²/day orally once daily for 5 consecutive days repeated every 21 days | 4 mg/dose if IV infusion, otherwise refer to regimen |
| Cervical cancer       | IV infusion dosage:
0.75 mg/m² IV over 30 minutes on Days 1, 2, and 3 repeated every 21 days in combination with cisplatin 50 mg/m² on Day 1 | 4 mg/dose if IV infusion, otherwise refer to regimen |

VI. Product Availability
- Capsules: 0.25 mg, 1 mg
- Lyophilized powder in single use vial for injection: 4-mg (free base)
VII. References

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J8705</td>
<td>Topotecan, oral, 0.25 mg</td>
</tr>
<tr>
<td>J9351</td>
<td>Injection, topotecan, 0.1 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Updated FDA approved indication for Hycamtin capsules and injection. Updated study information from guidelines and package insert. Added safety/appendix information. Added age requirement and safety information to both algorithms. Shortened the approval period to 3 months in Figure 2 in support of monitoring and efficacy requirements/guidelines. Took out request for lab documentation from algorithms; questions sufficient.</td>
<td>06.15</td>
<td>06.15</td>
</tr>
<tr>
<td>Policy converted to new template. Age restriction removed. Lung cancer – FDA approved use – edited to more closely align with PI indication language. Cervical cancer – FDA approved use “curable with surgery and/or radiotherapy” is edited to read “not amenable to curative treatment” per PI. Ovarian cancer – FDA approved use – criteria regarding failed chemo with platinum containing regimen and disease recurrence within 6 months is edited to align with the PI language. All NCCN compendium uses added.</td>
<td>05.16</td>
<td>06.16</td>
</tr>
<tr>
<td>All indications: initial: removed safety requirement related to hypersensitivity reactions to topotecan; edited boxed warning information regarding bone marrow suppression language to align with PI; modified approval duration for initial and continued to 6 and</td>
<td>05.17</td>
<td>06.17</td>
</tr>
</tbody>
</table>
Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.13.18</td>
<td>05.18</td>
</tr>
<tr>
<td>12.19.19</td>
<td>05.19</td>
</tr>
<tr>
<td>02.11.20</td>
<td>05.20</td>
</tr>
</tbody>
</table>

12 months, respectively; added requirements related to FDA max dose and the option to submit literature for relevant off-label use/dose (also added to re-auth); re-auth: removed reasons to discontinue. Small cell lung cancer: edited FDA approved use for capsules. Updated additional NCCN compendium uses and removed acute myeloid leukemia.

2Q 2018 annual review: HIM added; summarized NCCN and FDA approved uses for improved clarity; added specialist involvement in care; added continuity of care statement; added age; removed lab requirements pertaining to baseline neutrophil and platelet counts; off-label NCCN recommended uses (e.g., bone cancer, CNS cancers, etc.): updated to include only category 2A (removed 2b); added requirement that request is for the injectable formulation, added dosing statement and initial approval duration of 6 months; references reviewed and updated.

2Q 2019 annual review: Commercial line of business added; capsules added as an option for Merkel cell carcinoma and intrathecal route notated for leptomeningeal metastasis per NCCN; references reviewed and updated.

2Q 2020 annual review: no significant changes; references reviewed and updated.

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.
This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2011 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.